Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) Return on assets
Eli Lilly and Company's return on assets over the twelve months to 30 June 2026 was 22.0%, up 0.4 percentage points from fiscal 2025 (21.6%). Over the past ten years it has ranged from −0.49% (fiscal 2017) to 21.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 2.57% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 21.6% | 6.75 |
| FY2024 | 14.8% | 5.61 |
| FY2023 | 9.23% | (3.48) |
| FY2022 | 12.7% | 1.01 |
| FY2021 | 11.7% | (2.72) |
| FY2020 | 14.4% | (5.58) |
| FY2019 | 20.0% | 12.73 |
| FY2018 | 7.27% | 7.76 |
| FY2017 | −0.49% | (7.85) |
| FY2016 | 7.36% | 0.66 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LLY Eli Lilly and Company | 22.0% |
| NVS Novartis AG compare | 11.3% |
| AMGN Amgen Inc. compare | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| ABBV AbbVie Inc. compare | 4.61% |
| MRK Merck & Co., Inc. compare | 2.57% |
| PFE Pfizer Inc. compare | 2.13% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.57% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement